BPC-157

BPC-157 is a synthetic pentadecapeptide — a linear 15-residue sequence with no cysteines, no disulfide bridges, and no cyclisation or fatty-acid modification. Its sequence corresponds to a partial region of a larger protein described in the gastric-juice literature, and the peptide as supplied is produced by solid-phase synthesis rather than isolated from tissue. The absence of secondary structural constraints is itself a notable feature: it is a small, flexible, highly water-soluble peptide, which is one reason it recurs so often as a model compound in peptide-handling and stability method development.

The sequence entered the literature in the 1990s through work on gastric protective fractions, and the designation "body protection compound" reflects the naming convention of that original programme rather than any characterised function. Because interest in it grew rapidly outside the small group of laboratories that first described it, the primary literature is unusually concentrated, and reviews frequently note that independent replication remains limited. That context is relevant to anyone designing an experiment around it: the compound is a well-defined chemical entity, but the surrounding evidence base is narrower than the volume of secondary commentary suggests.

Research reported in the primary literature examines it in relation to nitric-oxide pathway signalling, growth-factor receptor expression (VEGFR2 among them), and angiogenic and cell-migration readouts in cultured cells and in animal models of tissue injury. Further work has looked at interactions with dopaminergic and serotonergic systems and at gastrointestinal mucosal models. These are described as areas of investigation; the findings reported in those studies belong to the investigators who produced them and are not represented here as established effects, uses, or outcomes.

Analytical verification is disproportionately important for this sequence. Because it is short, unmodified, and inexpensive to synthesise, the material circulating under this name varies widely in provenance, and truncated or deletion sequences arising from incomplete coupling during synthesis are the characteristic impurity class. HPLC resolves those closely related species and mass spectrometry confirms the intact molecular mass, so identity and purity data at the batch level are what make results comparable between experiments — an unverified sequence is the most common uncontrolled variable in this research area.

It is most often set alongside TB-500 in comparative studies, and the two are frequently confused despite being structurally unrelated: BPC-157 is a synthetic 15-residue sequence with no natural full-length parent in circulation, whereas TB-500 corresponds to a fragment of thymosin β4 and carries a defined actin-binding motif. Comparisons between them are comparisons of two different chemistries studied in partially overlapping tissue-model contexts, not of variants within one peptide family.